Related Experiment Videos
The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function
R Dall'Olio1, R Rimondini, O Gandolfi
1Department of Pharmacology, University of Bologna, Italy.
Psychopharmacology
|April 1, 1995
Summary
Competitive NMDA antagonists may aid Parkinson's disease treatment by enhancing dopaminergic function without motor impairment. These compounds show potential for therapeutic use in managing the condition.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- NMDA receptor antagonists are crucial in neuroscience research.
- Understanding the differential effects of competitive and non-competitive NMDA antagonists is vital for drug development.
Purpose of the Study:
- To investigate the behavioral effects of competitive (CGP 43487, APV) and non-competitive (MK-801) NMDA receptor antagonists in rats.
- To evaluate the potential of these antagonists in modulating dopaminergic activity and their therapeutic implications for Parkinson's disease.
Main Methods:
- Administration of varying doses of MK-801, CGP 43487, and APV to rats.
- Assessment of locomotor activity and rota-rod test performance.
- Evaluation of behavioral responses to apomorphine challenge after antagonist pretreatment.
Main Results:
- MK-801 dose-dependently altered locomotor activity; CGP 43487 and APV inhibited locomotion at high doses.
- CGP 43487 did not impair rota-rod performance, unlike MK-801 and APV.
- Both antagonist types potentiated apomorphine-induced behaviors, with competitive antagonists showing a more pronounced effect on licking and gnawing without motor deficits.
Conclusions:
- Competitive NMDA antagonists facilitate dopaminergic function without causing motor impairment.
- These findings suggest that competitive NMDA antagonists could be beneficial as adjunct therapies for Parkinson's disease.